Abstract:Pluripotent stem cells can differentiate into nearly all types of cells in the body. This unique potential provides significant promise for cell-based therapies to restore tissues or organs destroyed by injuries, degenerative diseases, aging, or cancer. The discovery of induced pluripotent stem cell (iPSC) technology offers a possible strategy to generate patient-specific pluripotent stem cells. However, because of concerns about the specificity, efficiency, kinetics, and safety of iPSC reprogramming, improvements or fundamental changes in this process are required before their effective clinical use. A chemical approach is regarded as a promising strategy to improve and change the iPSC process. Dozens of small molecules have been identified that can functionally replace reprogramming factors and significantly improve iPSC reprogramming. In addition to the prospect of deriving patient-specific tissues and organs from iPSCs, another attractive strategy for regenerative medicine is transdifferentiation-the direct conversion of one somatic cell type to another. Recent studies revealed a new paradigm of transdifferentiation: using transcription factors used in iPSC generation to induce transdifferentiation or called iPSC transcription factor-based transdifferentiation. This type of transdifferentiation not only reveals and uses the developmentally plastic intermediates generated during iPSC reprogramming but also produces a wide range of cells, including expandable tissue-specific precursor cells. Here, we review recent progress of small molecule approaches in the generation of iPSCs. In addition, we summarize the new concept of iPSC transcription factor-based transdifferentiation and discuss its application in generating various lineage-specific cells, especially cardiovascular cells.

Clinical Grade iPS Cells: Need for Versatile Small Molecules and Optimal Cell Sources

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Role of small molecules as drug candidates for reprogramming somatic cells into induced pluripotent stem cells: A comprehensive review

Progress in the Reprogramming of Somatic Cells

Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine

Inducible pluripotent stem cells: not quite ready for prime time?

Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells

Induced Neural Stem/precursor Cells for Fundamental Studies and Potential Application in Neurodegenerative Diseases

Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells

A Combined Chemical and Genetic Approach for the Generation of Induced Pluripotent Stem Cells

Human Ips Cell-Based Therapy Considerations Before Clinical Applications

[Progress and potential applications of induced pluripotent stem cell technology]

Remodeling of Epigenetic Landscape During Induced Somatic Cell Reprogramming

Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming

Small Molecules for Neural Stem Cell Induction

Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality

Small Molecules That Promote Self-Renewal of Stem Cells and Somatic Cell Reprogramming

The Future of Ips Cells in Advancing Regenerative Medicine.

Mechanism and Methods to Induce Pluripotency

Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications